Truffle Capital, an investor in Cytomics Systems, is a European private equity firm originally set up for investments in spin-offs from companies active in the IT, Energy, and Life Sciences sectors.
-
Cytomics Systems, a 2000 spin-off from French CNRS, is a biotechnology company developing proprietary novel drugs in two therapeutic areas: anti-fungals (anti-infectives) and oncology.
-
The company has developed an innovative screening technology for the discovery of new small molecules.
-
Following a €2.1 million investment by Truffle Capital in 2006, Cytomics Systems is actively pursuing R&D programs with the goal of developing proprietary antifungal and oncology drugs and leveraging its technology platform through alliances with pharmaceutical firms.
-
Truffle Capital board member: Philippe Pouletty, M.D